首页> 外文期刊>American Journal of Medicine and Medical Sciences >Study the Effect of Modifiable Risk Factors on Incidence and Prognostic Impact of Contrast Induced Nephropathy Post Coronary Interventions in Patients Admitted at AL-Azhar University Hospital, New Damietta, Egypt
【24h】

Study the Effect of Modifiable Risk Factors on Incidence and Prognostic Impact of Contrast Induced Nephropathy Post Coronary Interventions in Patients Admitted at AL-Azhar University Hospital, New Damietta, Egypt

机译:在埃及新达米埃塔AL-Azhar大学医院住院的患者中研究可修改的危险因素对冠状动脉介入治疗后造影剂诱发的肾病的发生率和预后影响的影响

获取原文
           

摘要

Background: Contrast-induced nephropathy (CIN) is defined as a relative (≥25%) or absolute (≥0.5 mg/dl; 44 μmol/l) increase in serum creatinine from baseline value. The aim of the work: Study the Incidence and the effect of Modifiable and non-modifiable risk factors for occurrence and prognostic impact of Contrast Induced Nephropathy post coronary interventions in patients admitted at AL-Azhar University Hospital, New Damietta, Egypt. Patients and methods: This study was conducted on 120 patients attended at the emergency unit, cardiac outpatient clinic and Internal medicine department of Al-Azhar university hospital New Damietta during the period from December 2014 and August 2015. They were presented by cardiac symptoms (chest pain, dyspnea, low cardiac output symptoms., acute coronary syndrome or chronic stable angina). They were subjected to coronary angiography and Percutaneous coronary Interventions after medical history taking, clinical examinations, and ECG findings suggestive of acute coronary syndrome, Basal serum creatinine before coronary angiography and percutaneous coronary Intervention Follow up serum creatinine 48 hours later and two weeks later, serum Na (meq/dl), serum K (meq/dl), serum uric acid (mg/dl), urine analysis, serum cholesterol, serum triglycerids, CBC, fasting and 2 hours post prandial blood glucose level, Hg A1 C. Results: 15 patients out of 120 patients developed contrast induced nephropathy (12.5%) 105 patients out of 120 patients didn’t develop contrast induced nephropathy (87.5%) so studied 120 patients divided into 2 groups: (group A) patients who developed contrast induced nephropathy (15 patients) and (group B) patients without contrast induced nephropathy (105) patients. There was a statistical significant increase of s. creatinine, follow up 48h s. creatinine after coronary interventions and follow up 2 weeks s. creatinine in group A in comparison to group B. There were statistically significant increase of D.M, HTN and congestive heart failure in group A in comparison to group B. Conclusion: Contrast nephropathy is a major cause of morbidity in patients undergoing coronary angiography or per cutaneous coronary interventions, risk factors for CIN such as diabetes mellitus, congestive heart failure, hypertension, and medications, high osmolality and high ionic content of contrast medium, large volume of contrast medium and recurrent contrast exposure all are included in increased incidence of occurrence of CIN and poor the prognosis. Proper selection of patients who undergo contrast imaging and pre-procedural preparations would be helpful to reduce the risk of CIN.
机译:背景:造影剂诱发的肾病(CIN)被定义为血清肌酐相对于基线值的相对(≥25%)或绝对(≥0.5mg / dl; 44μmol/ l)的相对增加。工作的目的:研究埃及新达米埃塔AL-Azhar大学医院接受冠状动脉介入治疗后造影剂诱发的肾病的发生率和可改变和不可改变的危险因素的发生率和影响以及预后影响。患者和方法:本研究针对2014年12月至2015年8月在Al-Azhar大学医院New Damietta的急诊科,心脏门诊和内科进行的120例患者进行了研究。疼痛,呼吸困难,低心输出量症状,急性冠状动脉综合征或慢性稳定型心绞痛)。他们在接受病史,临床检查和心电图检查结果提示急性冠状动脉综合征,基础血清肌酐在冠状动脉造影和经皮冠状动脉介入治疗后接受了冠状动脉造影和经皮冠状动脉介入治疗,分别在48小时和两周后随访血清肌酐。 Na(meq / dl),血清K(meq / dl),血清尿酸(mg / dl),尿液分析,血清胆固醇,血清甘油三酸酯,CBC,空腹和餐后2小时血糖,Hg A1 C.结果:120例患者中有15例发展为造影剂引起的肾病(12.5%)120例患者中有105例未发生造影剂引起的肾病(87.5%),因此,研究120例患者分为两组:(A组)造影剂引起的患者肾病(15例)和(B组)无造影剂的肾病患者(105例)。 s的统计显着增加。肌酐,随访48小时。肌酐在冠状动脉介入治疗后随访2周。与B组相比,A组的肌酐水平较高。A组的DM,HTN和充血性心力衰竭的发生率均高于B组。结论:造影剂肾病是冠状动脉造影或经皮穿刺术患者发病的主要原因冠状动脉介入治疗,CIN的危险因素(如糖尿病,充血性心力衰竭,高血压和药物治疗),造影剂的高渗透压和高离子含量,大量的造影剂和经常性的造影剂暴露都包括在CIN发生率增加中而且预后差。正确选择接受造影成像和术前准备的患者将有助于降低CIN的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号